EMTRICITABINA/TENOFOVIR DISOPROXIL STADA 200mg / 245mg tablets medication leaflet

J05AR03 • emtricitabine + tenofovir disoproxil • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

The combination of emtricitabine and tenofovir disoproxil is used for the treatment of HIV infection and for pre-exposure prophylaxis (PrEP). It works by inhibiting reverse transcriptase, preventing HIV replication.

The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, diarrhea, headaches, and decreased bone mineral density.

This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal function and bone density.

This medication is an effective option for managing HIV infection and preventing virus transmission, helping to improve patients' quality of life.